Blacks “have the highest death rate and shortest survival of any racial/ethnic group in the U.S. for most cancers,” according to the 2019-2021 American Cancer Society’s Cancer Facts & Figures for African Americans. Recognition of racial disparities in cancer is...
Cancer Clinical Trials
Category
ACCC Joins ASCO in Efforts to Improve Minority Representation in Cancer Clinical Trials
The Association of Community Cancer Centers (ACCC) has partnered with the American Society of Clinical Oncology (ASCO) in a collaborative effort to improve the participation of racial and ethnic minority populations in cancer clinical trials. The organizations call on...
More Intelligent Diagnosis & Matching Cancer Patients with Trials: Does the Precipio & TrialJectory Combo Overcome the Barriers?
New York area-based TrialJectory, an AI-powered technology platform venture supplying clinical trial-matching service supporting the clinical trial search, enrollment and engagement by cancer patients and their physicians, inked a new partnership with Precipio, a...
Clinical Trials May Be Next Best Option with Hidradenitis Supperativa
A 50% increase in clinical trials between 2017 and 2019, devoted to reducing symptoms of hidradenitis supperativa, may be a first-line option for Stage 2 and Stage 3 patients. Currently, adalimumab (brand name Humira) is the only medication approved by the...
Kaiser Permanente Participating in AbbVie-Sponsored International Clinical Trial Targeting Ovarian Cancer with PARP Inhibitor Called Veliparib
Kaiser Permanente Research radio recently interviewed Dr. Michael A Bookman, an oncologist and investigator with Kaiser, discussing his participation in an international clinical trial sponsored by AbbVie, focusing on a PARP inhibitor called Veliparib to treat ovarian...
UW-Madison Professor and Team To Lead The Nation’s Coordinating Center for the National Cancer Institute Cancer Prevention Clinical Trials Network
KyungMann Kim, a professor of biostatistics and medical informatics at the UW School of Medicine and Public Health, has received a five-year, $11.8 million award from the NCI of the National Institutes of Health to set up and manage the Cancer Prevention Clinical...
Time to Infuse Patient Navigation into Cancer Clinical Trials
TrialSite News reported in its African American clinical trial participation survey that best practices we have learned from experience on Medicaid-funded community care coordination initiatives could benefit not only minorities and at-risk patients but also all...
UCSF Does First Patient in Triple Combo Clinical Trial for Squamous Cell Head & Neck Cancer
TRIFECTA is an investigator-initiated, single-arm, open-label, clinical trial in which 35 evaluable Squamous Cell Head and Neck Cancer (SCCHN) patients will receive TAVO™, pembrolizumab and epacadostat. The primary endpoint of the study is overall response rate (ORR)...
Interim Data from Phase I/II CLASSICAL-Lung Trial Shows Signs of Efficacy in Advanced NSCLC
Vaccinex presented at 2019 Annual Meeting of the American Association for Cancer Research, demonstrating the combination of pepinemab with avelumab is effective and well tolerated to date in the ongoing phase I/II CLASSICAL-Lung trial. CLASSICAL-Lung is an open label,...
Pfizer and Merck KgAa discontinue phase III trial; Use of Avelumab analyzed in untreated ovarian cancer
Pfizer and Merck discontinued Javelin Ovarian PARP 100, the second phase III ovarian cancer trial to be discontinued within six months. In November of 2018 the JAVELIN Ovarian 200 trial was discontinued after it failed to meet endpoints. Javelin Ovarian PARP 100 was...
Hollings Cancer Center Supports Designs to Include Minorities in Cancer Clinical Trials
As reported in EurekAlert!, Marvella Ford, Ph.D. of the Hollings Cancer Center of the Medical University of South Carolina, as well as eight other cancer centers, has participated in an important study focusing on how to overcome disparities in cancer clinical...
Are Patient-Reported Outcomes in Open-Label Cancer Trials Biased?
Members of the U.S. Food and Drug Administration published a report in JAMA Oncology recently to address a concern that patient-reported outcomes (PROs) in open-label cancer trials could be biased. Given the expected growth of such open-label trials, the authors’...
FDA Rejects Karyopharm Therapeutics Request for Accelerated Approval for Myeloma Treatment
OncLive reports that the FDA’s Oncologic Drugs Advisory Committee (ODAC) rejected Karyopharm Therapeutics’ request for accelerated approval of selinexor for myeloma patients who have received received ≥3 prior lines of therapy and whose disease is refractory to at...
TrialWatch: ARCHES Trial Improves Metastatic Prostate Cancer Survival Rate
What is the ARCHES Trial? Sponsored by Astellas Pharma and Medivation (Pfizer), it is a study is to evaluate the efficacy of enzalutamide plus androgen deprivation therapy (ADT) as measured by radiographic progression-free survival (rPFS) based on central review. The...
University of PA School of Nursing on Advanced Care Planning with Cancer Clinical Trial Patients
Cancer clinical trials are an important option for patients with cancer. Yet, once a trial ends, patients still need care plans. Little is known at what point during clinical trial transitions to initiate planning discussions or how to educate research teams to...
Memorial Sloan Kettering Cancer Center Updates on the DORA Trial
URO Today included an update on the DORA trial, which is an open-label investigator-initiated phase III study sponsored by Memorial Sloan Kettering Cancer Center and managed by the Prostate Cancer Clinical Trials Consortium. Follow the link below to learn more about...
Investigator Profile: Dr. Miriam Knoll Discusses Social Media and Cancer Research
Dr. Miriam Knoll is a board-certified radiation oncologist at the John Theurer Cancer Center at Hackensack University Medical Center in New Jersey. She serves as Medical Director of the Department of Radiation Oncology at Hackensack University Medical...
NCI Trials For February 2019
The Cancer Letter recently published a list of National Cancer Institute cancer clinical trials ongoing during the month of February. TrialSite News includes the list below. Follow up with the Cancer Letter to learn more. They are an independent newsletter and a...
Massive Bio: Bringing World-Class Clinical Research to Patients and Patients to Clinical Research
Background Dr. Selin Kurnaz is on a mission to transform clinical research and ultimately improve healthcare outcomes. Blessed with brains, talent and drive, she earned a PhD from University of Michigan. Thereafter, she spent years in the buttoned-down world of big...
University of Florida Current Clinical Trials
As was reported in UF Health Cancer Center: Cancer is the leading cause of death for Floridians. Our state has the second highest cancer mortality rate in the nation, and the age group at the highest risk of developing cancer — 65 and older — is projected to grow by...